The Limited Times

Now you can see non-English news...

Big winner of the Covid, Pfizer multiplies the projects after the pandemic

2023-01-11T19:20:14.486Z


STORY - The laboratory boosts its R&D and multiplies acquisitions. Its non-Covid sales will double by 2030.


That was four years ago almost to the day.

Albert Bourla was speaking in San Francisco at the JPMorgan Conference, the annual high mass of the pharmaceutical sector.

His first intervention as CEO of Pfizer, this veteran of the house having taken charge a week earlier.

At the time, the American laboratory came out of a desert crossing linked to the expiration of the patents of several of its star drugs, including Viagra or Lipitor (anticholesterol).

Bourla is optimistic, convinced that a new era is dawning for the New York laboratory.

To discover

  • Pension reform: calculate the age at which you will finally leave

At the start of 2020, before the Covid surge, he was back in San Francisco but he was struggling to convince his peers that his portfolio of drugs in development would allow him to make a fresh start.

He regrets that Pfizer is underestimated by analysts.

Three years later, the Greek Albert Bourla is welcomed as a star, crowned with his success in the race for vaccines against Covid.

His…

This article is for subscribers only.

You have 84% left to discover.

Cultivating your freedom is cultivating your curiosity.

Keep reading your article for €0.99 for the first month

I ENJOY IT

Already subscribed?

Login

Source: lefigaro

All business articles on 2023-01-11

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.